06/10/2025 09:30
 Deutsche Bank and Ant International Announce Strategic Partnership to Provide Integrated Cross-Border Payment Solutions to Global Merchants

Deutsche Bank and Ant International have announced their strategic partnership to provide more comprehensive payment solutions for businesses of all sizes in Europe and Asia, by combining their expertise and leveraging Ant International’s proprietary tokenisation and AI-based FX technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609586580/en/From Left to Right: Sabih Behzad, Head of Digital Assets & Currencies Transfo...

07/14/2025 12:30
Stone Point Capital Closes Tenth Flagship Fund with $11.5 Billion of Committed Capital

Stone Point Capital LLC, a private equity firm focused on financial services and related industries, today announced the final closing of its tenth private equity fund, Trident X, with $11.5 billion in total commitments. Trident X exceeded its original target and hard cap of $9 billion and is approximately $2.5 billion larger than Trident IX, a $9 billion fund, which closed in 2022. Trident X received strong support from its existing investor base, as well as first-time commitments from a num...

07/14/2025 12:30
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology. “We are honored to be recognized at Premier’s 2025 Innovation Celebration....

07/14/2025 12:30
PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala

PCI Pharma Services (“PCI” or the “Company”), a world-leading global contract development and manufacturing organization (CDMO) focused on innovative biotherapies, today announced that it received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and supported with significant reinvestment by Mubadala Investment Company (“Mubadala”). Partners Group will also continue to support the Company with a minority investment. Financial terms of the private transaction we...